Venglustat PK in Hepatic Impairment

Phase 1, open-label trial of venglustat in Gaucher disease (GD), Fabry disease (FD), autosomal dominant polycystic kidney disease (ADPKD) and 1 more (4 arms), sponsored by Sanofi. Primary endpoints: Maximum venglustat plasma concentration observed at Day 20 and Area under the plasma concentration versus time curve extrapolated to infinity at Day 20. Started Jan 2023; status: completed.